Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
2.
Transplant Cell Ther ; 29(1): 43.e1-43.e8, 2023 01.
Article in English | MEDLINE | ID: mdl-36273783

ABSTRACT

Rituximab is commonly used as prevention, preemption, or therapeutically for post-transplant lymphoproliferative disorder (PTLD) after hematopoietic cell transplantation (HCT). Although it is generally assumed that rituximab toxicity (ie, infections resulting from hypogammaglobulinemia and neutropenia) is negligible in relation to mortality due to PTLD, limited evidence supports the validity of this assumption. We sought to determine the impact of rituximab on immunoglobulin levels, neutrophil count, infection density, and mortality outcomes. This study retrospectively analyzed 349 HCT recipients, 289 of whom did not receive rituximab and 60 of whom received rituximab preemptively or therapeutically at a median of 55 days post-transplantation. IgM, IgG, and IgA levels at 6 months and 12 months post-transplantation were lower in patients who received rituximab compared with those who did not (significant at P < .05 for IgM and IgA at 6 months and for IgM and IgG at 12 months). Rituximab recipients also had a higher incidence of severe neutropenia (<.5/nl) between 3 and 24 months (subhazard ratio [SHR], 2.3; P = .020). Regarding non-Epstein-Barr viral infections/PTLD, the rituximab group had a higher infection density between 3 and 24 months compared with the no-rituximab group (3.8 versus 1.6 infections per 365 days at risk; incidence rate ratio, 2.2; P < .001). The rituximab group also had a higher incidence of fatal infections (SHR, 3.1; P = .026), higher nonrelapse mortality (SHR, 2.4; P = .006), and higher overall mortality (hazard ratio, 1.7; P = .033). There were no significant between-group differences in the incidence of clinically significant graft-versus-host disease, graft failure, or relapse. Based on this study, rituximab given for PTLD is associated with substantial morbidity and mortality. Whether the benefit of preemptive rituximab outweighs the risk remains to be determined. © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.


Subject(s)
Epstein-Barr Virus Infections , Lymphoproliferative Disorders , Neutropenia , Humans , Rituximab/adverse effects , Epstein-Barr Virus Infections/complications , Epstein-Barr Virus Infections/drug therapy , Epstein-Barr Virus Infections/epidemiology , Herpesvirus 4, Human , Retrospective Studies , Risk Factors , Lymphoproliferative Disorders/epidemiology , Lymphoproliferative Disorders/etiology , Lymphoproliferative Disorders/drug therapy , Neutropenia/complications , Neutropenia/drug therapy , Immunoglobulin G , Immunoglobulin M/therapeutic use , Immunoglobulin A/therapeutic use
3.
Int J Mol Sci ; 23(24)2022 Dec 14.
Article in English | MEDLINE | ID: mdl-36555525

ABSTRACT

The persistence of graft-versus-host disease (GVHD) as the principal complication of allogeneic hematopoietic cell transplantation (HCT) demonstrates that HLA matching alone is insufficient to prevent alloreactivity. We performed molecular and functional characterization of 22 candidate cytokine genes for their potential to improve matching in 315 myeloablative, 10/10 HLA-matched donor−recipient pairs. Recipients of a graft carrying the -1082GG IL10 gene promoter region variant had a three-fold lower incidence of grade II−IV acute GVHD compared to IL10-1082AA graft recipients (SHR = 0.25, p = 0.005). This was most evident in matched unrelated donor (MUD) transplants, where the greatest alloreactivity is expected. IL10-1082GG transplants did not experience an increased incidence of relapse, and, consequently, overall survival was two-fold higher in IL10-1082GG MUD transplants (HR = 0.17, p = 0.023). Longitudinal post-transplant measurements demonstrated that -1082GG is a high-IL10-producing and -expressing genotype with attenuated CD8+ T-cell reconstitution. High post-transplant donor chimerism in T- and myeloid-cells (>95%) confirmed a predominant donor, rather than recipient, genotype effect on immune function and aGVHD. To date, this is the first study to report corroborating genome-to-cellular evidence for a non-HLA donor immunogenetic variant that appears to be protective against GVHD. The incorporation of IL10 variants in donor selection criteria and clinical-management decisions has the potential to improve patient outcomes.


Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Interleukin-10 , Humans , Genetic Predisposition to Disease , Graft vs Host Disease/genetics , Graft vs Host Disease/prevention & control , Hematopoietic Stem Cell Transplantation/adverse effects , Interleukin-10/genetics , Tissue Donors
4.
Cytotherapy ; 24(12): 1225-1231, 2022 12.
Article in English | MEDLINE | ID: mdl-36057497

ABSTRACT

BACKGROUND AIMS: The value of routine chimerism determination after myeloablative hematopoietic cell transplantation (HCT) is unclear, particularly in the setting of anti-thymocyte globulin (ATG)-based graft-versus-host disease (GVHD) prophylaxis. METHODS: Blood samples were collected at 3 months post-HCT from 558 patients who received myeloablative conditioning and ATG-based GVHD prophylaxis. Chimerism was assessed using multiplex polymerase chain reaction of short tandem repeats in sorted T cells (CD3+) and leukemia lineage cells (CD13+CD33+ for myeloid malignancies and CD19+ for B-lymphoid malignancies). ATG exposure was determined using a flow cytometry-based assay. The primary outcomes of interest were relapse and chronic GVHD (cGVHD). RESULTS: Incomplete (<95%) T-cell chimerism and leukemia lineage chimerism were present in 17% and 4% of patients, respectively. Patients with incomplete T-cell chimerism had a significantly greater incidence of relapse (36% versus 22%, subhazard ratio [SHR] = 2.03, P = 0.001) and lower incidence of cGVHD (8% versus 25%, SHR = 0.29, P < 0.001) compared with patients with complete chimerism. In multivariate modeling, patients with high post-transplant ATG area under the curve and any cytomegalovirus (CMV) serostatus other than donor/recipient seropositivity (non-D+R+) had an increased likelihood of incomplete T-cell chimerism. Patients with incomplete leukemia lineage chimerism had a significantly greater incidence of relapse (50% versus 23%, SHR = 2.70, P = 0.011) and, surprisingly, a greater incidence of cGVHD (45% versus 20%, SHR = 2.64, P = 0.003). CONCLUSIONS: High post-transplant ATG exposure and non-D+R+ CMV serostatus predispose patients to incomplete T-cell chimerism, which is associated with an increased risk of relapse. The increased risk of cGVHD with incomplete B-cell/myeloid chimerism is a novel finding that suggests an important role for recipient antigen-presenting cells in cGVHD pathogenesis.


Subject(s)
Cytomegalovirus Infections , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Leukemia , Humans , Graft vs Host Disease/prevention & control , Antilymphocyte Serum , Chimerism , Hematopoietic Stem Cell Transplantation/adverse effects , Risk Factors , Chronic Disease , Cytomegalovirus , Recurrence
6.
Transplant Cell Ther ; 28(1): 53.e1-53.e10, 2022 01.
Article in English | MEDLINE | ID: mdl-34607072

ABSTRACT

Post-transplant lymphoproliferative disorder (PTLD) is a potentially serious complication that occurs following hematopoietic cell transplantation (HCT), in which B cells transformed by Epstein-Barr virus (EBV) proliferate uncontrollably. It is unknown whether risk factors for the incidence of PTLD are identical to those for mortality due to PTLD, a clinically more important outcome. We sought to determine the risk factors influencing the incidence of PTLD and those influencing mortality due to PTLD in a cohort of 1184 allogenic HCT recipients. All patients were predisposed to PTLD, because their graft-versus-host disease (GVHD) prophylaxis included antithymocyte globulin. The overall PTLD incidence was 9.0%, and mortality due to PTLD was 1.1%. In multivariate analysis, risk factors for PTLD incidence include donor+/recipient- (D+/R-) EBV serostatus (subhazard ratio [SHR], 3.3; P = .002), use of a donor other than an HLA-matched sibling donor (non-MSD) (SHR, 1.7; P = .029), receipt of total body irradiation (TBI; SHR, 3.3; P = .008), and the absence of GVHD (SHR, 3.3; P < .001). The sole risk factor for mortality due to PTLD among all patients was D+/R- serostatus (SHR, 5.8; P = .022). Risk factors for mortality due to PTLD among patients who developed PTLD were use of a bone marrow (BM) graft (compared with peripheral blood stem cells [PBSCs]; SHR, 22.8; P < .001) and extralymphatic involvement (SHR, 14.6; P < .001). Interestingly, whereas the absence of GVHD was a risk factor for PTLD incidence, there was a trend toward the presence of GVHD as a risk factor for PTLD mortality (SHR, 4.2; P = .093). Likewise, whereas use of a BM graft was a risk factor for PTLD mortality, there was a trend toward use of a PBSC graft as a risk factor for PTLD incidence (SHR, 0.44; P = .179). Some risk factors for the incidence of PTLD are identical to the risk factors for mortality due to PTLD (ie, D+/R- serostatus), whereas other risk factors are disparate. Specifically, TBI was identified as a risk factor for PTLD incidence but not for PTLD mortality; the absence of GVHD was a risk factor for PTLD incidence, whereas the presence of GVHD was possibly a risk factor for PTLD mortality; and receipt of a PBSC graft was possibly a risk factor for PTLD incidence, whereas receipt of a BM graft was a risk factor for PTLD mortality.


Subject(s)
Epstein-Barr Virus Infections , Hematopoietic Stem Cell Transplantation , Lymphoproliferative Disorders , Epstein-Barr Virus Infections/epidemiology , Hematopoietic Stem Cell Transplantation/adverse effects , Herpesvirus 4, Human , Humans , Incidence , Lymphoproliferative Disorders/epidemiology , Risk Factors
7.
Cytotherapy ; 23(11): 1007-1016, 2021 11.
Article in English | MEDLINE | ID: mdl-34373186

ABSTRACT

BACKGROUND AIMS: Intensified immunosuppressive prophylaxis for graft-versus-host disease (GVHD) may be toxic and therefore warranted only in patients at high risk of developing GVHD. In patients who underwent allogeneic hematopoietic cell transplant at the authors' center, high serum soluble IL-2 receptor alpha (sIL-2Rα) and low IL-15 levels on day 7 post-transplant were found to predict a high risk of developing clinically significant GVHD (sGVHD), defined as grade 2-4 acute GVHD or moderate to severe chronic GVHD. METHODS: This was a prospective, phase 2 trial in which high-risk patients (serum sIL-2Rα >4500 ng/L or IL-15 <31 ng/L) received rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant. Controls consisted of patients who had their sIL-2Rα/IL-15 levels measured but did not participate in the trial. A total of 68 trial patients and 143 controls were accrued to this study. The primary endpoint was incidence of sGVHD. RESULTS: There was a reduction in sGVHD in high-risk trial patients (received day 8 ATG) compared with high-risk controls (did not receive day 8 ATG) (sub-hazard ratio [SHR] = 0.48, P < 0.05). There was no significant difference between the groups in overall survival or relapse; however, there was a greater incidence of non-GVHD-associated non-relapse mortality in high-risk trial patients (SHR = 3.73, P < 0.05), mostly related to infections. This may be due in part to the biomarkers ineffectively stratifying GVHD risk. CONCLUSIONS: Pre-emptive ATG therapy is both feasible and effective at reducing sGVHD without increasing relapse. Further mitigation strategies are needed to reduce the risk of infection associated with intensified GVHD prophylaxis. This study was registered at ClinicalTrials.gov (NCT01994824).


Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Antilymphocyte Serum , Biomarkers , Graft vs Host Disease/prevention & control , Humans , Prospective Studies , Transplantation, Homologous
8.
J Transl Int Med ; 8(3): 131-134, 2020 Sep.
Article in English | MEDLINE | ID: mdl-33062588

ABSTRACT

Coronavirus disease 2019 (COVID-19) has wreaked havoc and distressed economies worldwide. Countries have gone on lockdown of their economies to prevent the spread of the disease. This obviously led to collateral damage in the form of worsening healthcare for non-COVID-related conditions and is playing havoc with the world economy. Herein, we suggest novel strategies to prevent COVID-19 related complications, keeping in view the pathophysiology of the disease.

9.
Blood Adv ; 4(20): 5035-5039, 2020 10 27.
Article in English | MEDLINE | ID: mdl-33075136

ABSTRACT

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-driven coronavirus disease 2019 (COVID-19) has caused unprecedented human death and has seriously threatened the global economy. Early data suggest a surge in proinflammatory cytokines in patients with severe COVID-19, which has been associated with poor outcomes. We recently postulated that the inflammatory response in patients with severe COVID-19 disease is not inhibited by natural killer (NK) cells, resulting in a "cytokine storm." Here, we assessed the NK-cell functional activity and the associated cytokines and soluble mediators in hospitalized COVID-19 patients. Significantly impaired NK-cell counts and cytolytic activity were observed in COVID-19 patients when compared with healthy controls. Also, cytokines like interleukin 12 (IL12), IL15, and IL21 that are important for NK-cell activity were not detected systematically. Serum concentrations of soluble CD25 (sCD25)/soluble IL2 receptor α (sIL2-Rα) were significantly elevated and were inversely correlated with the percentage of NK cells. Impaired NK-cell cytolytic activity together with other laboratory trends including elevated sCD25 were consistent with a hyperinflammatory state in keeping with macrophage-activation syndrome. Our findings suggest that impaired counts and cytolytic activity of NK cells are important characteristics of severe COVID-19 and can potentially facilitate strategies for immunomodulatory therapies.


Subject(s)
Coronavirus Infections/immunology , Cytotoxicity, Immunologic , Killer Cells, Natural/immunology , Pneumonia, Viral/immunology , Adolescent , Adult , Aged , Betacoronavirus/immunology , COVID-19 , Coronavirus Infections/blood , Female , Humans , Inflammation/blood , Inflammation/immunology , Interleukin-2 Receptor alpha Subunit/blood , Interleukin-2 Receptor alpha Subunit/immunology , Interleukins/blood , Interleukins/immunology , Lymphocyte Count , Male , Middle Aged , Pandemics , Pneumonia, Viral/blood , SARS-CoV-2 , Severity of Illness Index , Young Adult
10.
Clin Transplant ; 34(9): e14018, 2020 09.
Article in English | MEDLINE | ID: mdl-32573834

ABSTRACT

Optimal conditioning and graft-vs-host disease (GVHD) prophylaxis for hematopoietic cell transplantation (HCT) are unknown. Here, we report on outcomes after low toxicity, myeloablative conditioning consisting of fludarabine, busulfan, and 4 Gy total body irradiation, in combination with thymoglobulin and post-transplant methotrexate and cyclosporine. We retrospectively studied 700 patients with hematologic malignancies who received blood stem cells from 7 to 8/8 HLA-matched unrelated or related donors. Median follow-up of surviving patients was 5 years. At 5 years, overall survival (OS), relapse-free survival (RFS), and chronic GVHD/relapse-free survival (cGRFS) were 58%, 55%, and 40%. Risk factors for poor OS, RFS, and cGRFS were (1). high to very high disease risk index (DRI), (2). high recipient age, and (3). cytomegalovirus (CMV)-seropositive recipient with seronegative donor (D-R+). The latter risk factor applied particularly to patients with lymphoid malignancies. Neither donor other than HLA-matched sibling (7-8/8 unrelated) nor one HLA allele mismatch was risk factors for poor OS, RFS, or cGRFS. In conclusion, the above regimen results in excellent long-term outcomes. The outcomes are negatively impacted by older age, high or very high DRI, and CMV D-R+ serostatus, but not by donor unrelatedness or one HLA allele mismatch.


Subject(s)
Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Aged , Antilymphocyte Serum/therapeutic use , Busulfan/therapeutic use , Graft vs Host Disease/etiology , Graft vs Host Disease/prevention & control , Humans , Myeloablative Agonists/therapeutic use , Neoplasm Recurrence, Local , Retrospective Studies , Transplantation Conditioning , Treatment Outcome , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use , Whole-Body Irradiation
11.
Bone Marrow Transplant ; 55(7): 1282-1289, 2020 07.
Article in English | MEDLINE | ID: mdl-32231249

ABSTRACT

Atopy is excessive production of IgE in response to allergens. We evaluated in patients undergoing allogeneic hematopoietic cell transplantation (HCT) the following hypotheses: (1) Atopy is "curable" in atopic patients receiving HCT from a nonatopic donor (D-R+), and (2) Atopy is transferable from atopic donors to nonatopic recipients (D+R-). Atopic patients with atopic donors (D+R+) and non-atopic patients with non-atopic donors (D-R-) served as controls. We measured levels of multiallergen-specific IgE (A-IgE, atopy defined as ≥0.35 kUA/L) in sera from 54 patients and their donors pre HCT and from the patients at ≥2 years post HCT. Only 7/12 (58%) D- R+ patients became nonatopic after HCT. Only 1/11 (9%) D+R- patients became atopic. Eleven of 13 (85%) D-R- patients remained nonatopic. Unexpectedly, 11/18 (61%) D+R+ patients became nonatopic. In conclusion, contrary to our hypothesis and previous reports, the "cure" of atopy may occur in only some D-R+ patients and the transfer of atopy may occur rarely. The "cure" may not be necessarily due to the exchange of atopic for nonatopic immune system, as the "cure" may also occur in D+R+ patients.


Subject(s)
Hematopoietic Stem Cell Transplantation , Hypersensitivity, Immediate , Allergens , Humans , Immunoglobulin E
12.
Cytotherapy ; 22(1): 27-34, 2020 01.
Article in English | MEDLINE | ID: mdl-31889628

ABSTRACT

BACKGROUND: International guidelines for Pneumocystis jirovecii pneumonia (PJP) prevention recommend prophylaxis for ≥6 months following allogeneic hematopoietic cell transplantation, and longer in patients with graft-versus-host disease (GVHD) or on immunosuppressive therapy (IST). These recommendations are based on cohorts of patients who did not routinely receive anti-thymocyte globulin (ATG) for GVHD prophylaxis. METHODS: We performed a retrospective chart review of 649 patients, all of whom received ATG as part of GVHD prophylaxis. RESULTS: The cumulative incidence of definite PJP was 3.52% at both 3 and 5 years (median follow up, 1648 days for survivors). PJP occurred in 13 non-GVHD patients between days 207 and 508, due in part to low CD4 T-cell counts (<200 CD4 T cells/µL). PJP occurred in eight GVHD patients between days 389 and 792, due in part to non-adherence to PJP prophylaxis guidelines (discontinuation of PJP prophylaxis at <3 months after discontinuation of IST). Breakthrough PJP infection was not observed in patients receiving prophylaxis with cotrimoxazole, dapsone or atovaquone, whereas three cases were observed with inhaled pentamidine. DISCUSSION: In conclusion, for non-GVHD patients receiving ATG-containing GVHD prophylaxis, 6 months of PJP prophylaxis is inadequate, particularly if the CD4 T-cell count is <200 cells/µL or if there is a high incidence of PJP in the community. For patients with GVHD receiving ATG-containing GVHD prophylaxis, continuing PJP prophylaxis until ≥3 months post-discontinuation of IST is important. Cotrimoxazole, dapsone and atovaquone are preferred over inhaled pentamidine.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Immunosuppression Therapy/adverse effects , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/epidemiology , Adolescent , Adult , Aged , Antilymphocyte Serum/adverse effects , Antilymphocyte Serum/therapeutic use , Atovaquone/therapeutic use , CD4 Lymphocyte Count , Dapsone/therapeutic use , Female , Graft vs Host Disease/drug therapy , Humans , Immunocompromised Host/immunology , Incidence , Lymphopenia/chemically induced , Lymphopenia/immunology , Male , Middle Aged , Pentamidine/adverse effects , Pentamidine/therapeutic use , Pneumonia, Pneumocystis/drug therapy , Pneumonia, Pneumocystis/prevention & control , Retrospective Studies , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Young Adult
13.
J Transl Int Med ; 8(4): 274-275, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33511055
14.
Cytotherapy ; 21(8): 886-894, 2019 08.
Article in English | MEDLINE | ID: mdl-31253496

ABSTRACT

BACKGROUND: Association between low counts of herpesvirus-specific T cells and subsequent relapse of hematologic malignancy has been shown in two retrospective studies. METHODS: Here we present results of a prospective validation study. Multiple subsets of Epstein-Barr virus (EBV)-specific T cells were measured in 69 patients on day 56 and 84, using intracellular flow cytometry after incubation of blood mononuclear cells (MNCs) with EBV peptides or lysate. RESULTS: All EBV T-cell subsets measured, both on day 56 and 84, were lower in patients who did versus did not subsequently relapse. This was most significant for day 56 EBV lysate-stimulated CD8 T cells producing interferon-gamma. Patients with day 56 counts of this subset >5/µL had a significantly lower likelihood of relapse compared with those with ≤5/µL (subhazard ratio, 5.7; P = 0.007). Similar significant associations were shown for a total of seven EBV T-cell subsets on day 56 and nine subsets on day 84. However, sensitivity and specificity of relapse prediction using the count of any subset was low (area under the curve of receiver-operator characteristic curve was <0.8). DISCUSSION: In conclusion, the association between EBV T-cell counts and subsequent relapse is valid. However, its clinical utility appears to be limited.


Subject(s)
Epstein-Barr Virus Infections/virology , Hematologic Neoplasms/therapy , Peripheral Blood Stem Cell Transplantation/adverse effects , T-Lymphocyte Subsets/virology , Transplantation, Homologous/adverse effects , Adult , Aged , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Cryopreservation , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/pathology , Female , Hematologic Neoplasms/epidemiology , Hematologic Neoplasms/pathology , Herpesvirus 4, Human/immunology , Humans , Incidence , Interferon-gamma/metabolism , Lymphocyte Count , Male , Middle Aged , Peripheral Blood Stem Cell Transplantation/methods , Prospective Studies , ROC Curve , T-Lymphocyte Subsets/immunology , Tissue Donors , Treatment Outcome , Young Adult
15.
Cytotherapy ; 20(5): 706-714, 2018 05.
Article in English | MEDLINE | ID: mdl-29580864

ABSTRACT

BACKGROUND: Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of allogeneic hematopoietic cell transplantation (HCT). Epstein-Barr virus (EBV) reactivation (detectable DNAemia) predisposes to the development of PTLD. METHODS: We retrospectively studied 306 patients monitored for EBV DNAemia after Thymoglobulin-conditioned HCT to determine the utility of the monitoring in the management of PTLD. DNAemia was monitored weekly for ≥12 weeks post-transplantation. RESULTS: Reactivation was detected in 82% of patients. PTLD occurred in 14% of the total patients (17% of patients with reactivation). PTLD was treated with rituximab only when and if the diagnosis was established. This allowed us to evaluate potential DNAemia thresholds for pre-emptive therapy. We suggest 100,000-500,000 IU per mL whole blood as this would result in unnecessary rituximab administration to only 4-20% of patients and near zero mortality due to PTLD. After starting rituximab (for diagnosed PTLD), sustained regression of PTLD occurred in 25/25 (100%) patients in whom DNAemia became undetectable. PTLD progressed or relapsed in 12/17 (71%) patients in whom DNAemia was persistently detectable. DISCUSSION: In conclusion, for pre-emptive therapy of PTLD, we suggest threshold DNAemia of 100,000-500,000 IU/mL. Persistently detectable DNAemia after PTLD treatment with rituximab appears to have 71% positive predictive value and 100% negative predictive value for PTLD progression/relapse.


Subject(s)
DNA, Viral/blood , Hematopoietic Stem Cell Transplantation/adverse effects , Herpesvirus 4, Human/genetics , Lymphoproliferative Disorders/etiology , Lymphoproliferative Disorders/virology , Adolescent , Adult , Aged , Epstein-Barr Virus Infections/blood , Epstein-Barr Virus Infections/immunology , Epstein-Barr Virus Infections/virology , Female , Herpesvirus 4, Human/immunology , Humans , Lymphoproliferative Disorders/blood , Lymphoproliferative Disorders/drug therapy , Male , Middle Aged , Retrospective Studies , Rituximab/therapeutic use , Virus Activation , Young Adult
16.
Clin Transplant ; 32(1)2018 01.
Article in English | MEDLINE | ID: mdl-29114932

ABSTRACT

Epstein-Barr virus (EBV)-induced post-transplant lymphoproliferative disorder (PTLD) occurs frequently when rabbit antithymocyte globulin (ATG) is used in hematopoietic cell transplant (HCT) conditioning. We retrospectively studied 554 patients undergoing ATG-conditioned myeloablative HCT. Strategies used to minimize mortality due to PTLD were either therapy of biopsy-diagnosed PTLD in the absence of EBV DNAemia monitoring (n = 266) or prompt therapy of presumed PTLD (based on clinical/radiologic signs and high EBV DNAemia, in the setting of weekly EBV DNAemia monitoring) (n = 199). Both strategies resulted in similar mortality due to PTLD (0.7% vs 1% at 2 years, P = .43) and similar overall survival (63% vs 67% at 2 years, P = .23) even though there was a trend toward higher PTLD incidence with the prompt therapy. Donor positive with recipient negative EBV (D+R-) serostatus was a risk factor for developing PTLD. Older patient age, HLA-mismatched donor, and graft-versus-host disease were not associated with increased risk of PTLD. In summary, in ATG-conditioned HCT, D+R- serostatus, but not older age, mismatched donor or GVHD is a risk factor for developing PTLD. EBV DNAemia monitoring may be a weak risk factor for developing/diagnosing PTLD; the monitoring coupled with prompt therapy does not improve survival.


Subject(s)
Antilymphocyte Serum/administration & dosage , Epstein-Barr Virus Infections/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Herpesvirus 4, Human/pathogenicity , Lymphoproliferative Disorders/etiology , Transplantation Conditioning/adverse effects , Adolescent , Adult , Aged , Child , Epstein-Barr Virus Infections/virology , Female , Follow-Up Studies , Herpesvirus 4, Human/isolation & purification , Humans , Immunosuppressive Agents/administration & dosage , Lymphoproliferative Disorders/pathology , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , Viral Load , Young Adult
17.
J Card Surg ; 32(12): 830-832, 2017 Dec.
Article in English | MEDLINE | ID: mdl-29098719

ABSTRACT

Congenital aortico-left ventricular tunnel requires surgical repair during childhood. Long-term surveillance is essential in these patients given the risk for aortic aneurysm development in adulthood. We describe an aortic root replacement for an aortic aneurysm five decades following the closure of an aortic-left ventricular tunnel.


Subject(s)
Aorta/abnormalities , Aortic Aneurysm/surgery , Heart Defects, Congenital/surgery , Heart Ventricles/abnormalities , Postoperative Complications/surgery , Vascular Grafting/methods , Aorta/surgery , Aortic Aneurysm/etiology , Female , Heart Ventricles/surgery , Humans , Middle Aged
18.
Biol Blood Marrow Transplant ; 22(9): 1654-1663, 2016 09.
Article in English | MEDLINE | ID: mdl-27246372

ABSTRACT

Although previous studies involving allogeneic hematopoietic cell transplantation (HCT) without in vivo T cell depletion by rabbit antithymocyte globulin (ATG) have reported a substantial survival difference between D-R- and D+R- patients, but little to no survival difference between D-R+ and D+R+ patients (D, donor; R, recipient; +, cytomegalovirus [CMV] seropositive; -, CMV seronegative), whether this applies to HCT using ATG is unknown. We studied 928 patients who underwent myeloablative HCT for hematologic malignancies in Alberta between 1999 and 2014 who received graft-versus-host disease (GVHD) prophylaxis using ATG (Thymoglobulin, 4.5 mg/kg) in addition to methotrexate and cyclosporine. D-R- and D+R- patients had similar survival (no significant difference). D-R+ patients had a substantially lower survival than D+R+ patients (41% versus 59% at 5 years; P = .001). This difference was attributed to higher nonrelapse mortality, apparently due to higher GVHD-associated mortality. Survival rates were also lower for D-R+ HLA-matched sibling transplant recipients compared with D+R+ HLA-matched unrelated donor transplant recipients (44% versus 66% at 5 years; P = .009). In conclusion, when using ATG, choosing a seronegative donor for a seronegative patient is relatively unimportant, whereas choosing a seropositive donor for a seropositive patient is important, even if this requires the use of a seropositive matched unrelated donor graft.


Subject(s)
Antilymphocyte Serum/therapeutic use , Cytomegalovirus/immunology , Hematopoietic Stem Cell Transplantation/methods , Seroepidemiologic Studies , Transplantation Conditioning/methods , Adolescent , Adult , Aged , Alberta , Child , Female , Graft vs Host Disease/drug therapy , Graft vs Host Disease/mortality , Hematologic Neoplasms/mortality , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Male , Middle Aged , Myeloablative Agonists/therapeutic use , Survival Analysis , Tissue Donors , Transplant Recipients , Treatment Outcome , Young Adult
19.
J Int Oral Health ; 6(2): 40-4, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24876701

ABSTRACT

BACKGROUND: Purpose of this study was to modify the stethoscope which can auscultate the temporomandibular joint (TMJ) sounds more precisely than conventional stethoscope, and fabrication of stethoscope compatible software which analyses the auscultated sound and gives documentary evidence of that analysis in the form of graph. MATERIALS & METHODS: The conventional stethoscope was modified by attaching a custom made soundscope with a recording device which can be placed in external auditory meatus (EAM) for auscultation of TMJ sounds. When this small and smooth end of custom made soundscope of modified stethoscope is placed in EAM & connected with specially developed software it records the TMJ sounds & analyzes them in form of graph. RESULTS: Fabrication of modified stethoscope with software records the auscultated sound as a sound wave in form of graph and analyses this sound wave graph to give graphic evidence of prominent intensity at prominent frequency as spectrum analysis graph, and duration of that sound as a sound length graph. CONCLUSION: The use of modified stethoscope with software increases the accuracy of auscultation of TMJ sounds without any patient's discomfort and helps in diagnosis of TMJ disorders. The modified stethoscope with software for auscultation of TMJ sounds results in more precise auscultation & analysis of TMJ for sounds even of low intensity & frequency. How to cite the article: Dagar SR, Turakiya V, Pakhan AJ, Jaggi N, Kalra A, Vaidya V. Modified stethoscope for auscultation of temporomandibular joint sounds. J Int Oral Health 2014;6(2):40-4.

20.
Conn Med ; 78(9): 537-9, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25675594

ABSTRACT

Blastomycosis is a disease caused by the fungus Blastomyces dermatitidis. Pulmonary blastomycosis is the most common form of blastomycosis. Disseminated blastomycosis is the fulminant form of the disease, with rare reports of peritoneal cavity involvement. We report a case of extensive form of the disease presenting initially as abdominal pain and mimicking peritoneal carcinomatosis.


Subject(s)
Blastomycosis/complications , Blastomycosis/diagnosis , Carcinoma/diagnosis , Peritoneal Neoplasms/diagnosis , Abdominal Pain/etiology , Ascitic Fluid/microbiology , Blastomyces/isolation & purification , Blastomycosis/drug therapy , Diagnosis, Differential , Humans , Male , Middle Aged , Nausea/etiology , Peritoneal Diseases/microbiology , Vomiting/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...